Research programme: antibody therapeutics - iMetabolic Biopharma
Latest Information Update: 28 Dec 2022
At a glance
- Originator iMetabolic Biopharma
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lipid metabolism disorders
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for research development in Lipid-metabolism-disorders in USA (Parenteral)
- 18 Dec 2020 iMetabolic Biopharma expands its existing licensing agreement with Ligand Pharmaceuticals for additional OmniAb species and technologies
- 17 Feb 2020 iMetabolic Biopharma plans to initiates toxicological studies in Q2 2020